Xiao et al., 2018 - Google Patents
Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem …Xiao et al., 2018
View HTML- Document ID
- 12887501401599643444
- Author
- Xiao Z
- Tang F
- Zhao Y
- Han G
- Yin N
- Li X
- Chen B
- Han S
- Jiang X
- Yun C
- Zhao C
- Cheng S
- Zhang S
- Dai J
- Publication year
- Publication venue
- Cell transplantation
External Links
Snippet
Stem cells and biomaterials transplantation hold a promising treatment for functional recovery in spinal cord injury (SCI) animal models. However, the functional recovery of complete SCI patients was still a huge challenge in clinic. Additionally, there is no clinical …
- 208000008513 Spinal Cord Injury 0 title abstract description 114
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem cells | |
| Zhao et al. | Clinical study of NeuroRegen scaffold combined with human mesenchymal stem cells for the repair of chronic complete spinal cord injury | |
| Chen et al. | A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries | |
| Tabakow et al. | Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging | |
| Silvestro et al. | Stem cells therapy for spinal cord injury: an overview of clinical trials | |
| Ahuja et al. | Recent advances in managing a spinal cord injury secondary to trauma | |
| Zhu et al. | Phase I–II clinical trial assessing safety and efficacy of umbilical cord blood mononuclear cell transplant therapy of chronic complete spinal cord injury | |
| Lees et al. | Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis | |
| Jarocha et al. | Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury | |
| Huang et al. | A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy | |
| Chen et al. | NeuroRegen scaffolds combined with autologous bone marrow mononuclear cells for the repair of acute complete spinal cord injury: a 3-year clinical study | |
| Cao et al. | Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat | |
| Ackery et al. | A global perspective on spinal cord injury epidemiology | |
| Monto | Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis | |
| Hu et al. | Progress in clinical trials of cell transplantation for the treatment of spinal cord injury: how many questions remain unanswered? | |
| Zhou et al. | Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up | |
| Huang et al. | Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury | |
| Himes et al. | Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord | |
| Kesikburun et al. | Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up | |
| Oraee-Yazdani et al. | Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome | |
| Hess et al. | A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke | |
| Volarevic et al. | Stem cell-based therapy for spinal cord injury | |
| Terenghi et al. | The nerve injury and the dying neurons: diagnosis and prevention | |
| Wu et al. | Clinical observation of fetal olfactory ensheathing glia transplantation (OEGT) in patients with complete chronic spinal cord injury | |
| Chen et al. | Transplantation of mesenchymal stem cells for spinal cord injury: a systematic review and network meta-analysis |